Form 8-K - Current report:
SEC Accession No. 0001140361-25-040444
Filing Date
2025-11-05
Accepted
2025-11-05 08:36:27
Documents
14
Period of Report
2025-11-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20057479x6_8k.htm   iXBRL 8-K 30291
2 EXHIBIT 5.1 ny20057479x6_ex5-1.htm EX-5.1 96171
6 ny20057479x6_ex5-1img01.jpg GRAPHIC 408709
  Complete submission text file 0001140361-25-040444.txt   833072

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atai-20251105.xsd EX-101.SCH 3857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20251105_lab.xml EX-101.LAB 22691
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20251105_pre.xml EX-101.PRE 16547
17 EXTRACTED XBRL INSTANCE DOCUMENT ny20057479x6_8k_htm.xml XML 4219
Mailing Address PROF. J.H. BAVINCKLAAN 7 AMSTELVEEN Netherlands 1183
Business Address PROF. J.H. BAVINCKLAAN 7 AMSTELVEEN Netherlands 1183 49 89 2153 9035
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 251451944
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)